Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 217

1.

Rebound Vertebral Fractures in a Patient With Lung Cancer After Oncology-Dose Denosumab Discontinuation: A Cautionary Tale.

Tyan A, Patel SP, Block S, Hughes T, McCowen KC.

Mayo Clin Proc Innov Qual Outcomes. 2019 May 27;3(2):235-237. doi: 10.1016/j.mayocpiqo.2019.02.003. eCollection 2019 Jun.

2.

Mechanisms of voice control related to prosody in autism spectrum disorder and first-degree relatives.

Patel SP, Kim JH, Larson CR, Losh M.

Autism Res. 2019 Jun 12. doi: 10.1002/aur.2156. [Epub ahead of print]

PMID:
31187944
3.

Voluntary exercise may activate components of pro-survival risk pathway in the rat heart and potentially modify cell proliferation in the myocardium.

Lonek L, Puhova A, Griecsova-Kindernay L, Patel SP, Zohdi V, Jezova D, Ravingerova T.

Physiol Res. 2019 Jun 6. [Epub ahead of print]

4.

Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study.

Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann S, Piulats J, Kivelä TT, Pfoehler C, Bhatia S, Huppert P, Van Iersel LBJ, De Vries IJM, Penel N, Vogl T, Cheng T, Fiorentini G, Mouriaux F, Tarhini A, Patel PM, Carvajal R, Joshua AM.

Ann Oncol. 2019 May 31. pii: mdz176. doi: 10.1093/annonc/mdz176. [Epub ahead of print]

PMID:
31150059
5.

Effect of Heavy Mass Ion (Gold) and Light Mass Ion (Boron) Irradiation on Microstructure of Tungsten.

Sharma P, Maya P, Akkireddy S, Raole PM, Tyagi AK, Attri A, Kulriya PK, Bajpai PK, Mishra S, Patel SP, Trivedi T, Khan KB, Deshpande SP.

Microsc Microanal. 2019 May 28:1-7. doi: 10.1017/S1431927619000667. [Epub ahead of print]

PMID:
31134875
6.

GABABR-Mediated Paraneoplastic Limbic Encephalitis Due To Thymic Small Cell Carcinoma.

Bordin-Wosk T, Patel SP, Horman SF.

J Gen Intern Med. 2019 May 6. doi: 10.1007/s11606-019-05040-4. [Epub ahead of print]

PMID:
31062226
7.

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies.

Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00180. Epub 2019 Jan 22.

8.

Extrarenal Signs of Proximal Renal Tubular Acidosis Persist in Nonacidemic Nbce1b/c-Null Mice.

Salerno EE, Patel SP, Marshall A, Marshall J, Alsufayan T, Mballo CSA, Quade BN, Parker MD.

J Am Soc Nephrol. 2019 Jun;30(6):979-989. doi: 10.1681/ASN.2018050545. Epub 2019 Apr 30.

PMID:
31040187
9.

Cholestatic pruritus: Emerging mechanisms and therapeutics.

Patel SP, Vasavda C, Ho B, Meixiong J, Dong X, Kwatra SG.

J Am Acad Dermatol. 2019 Apr 19. pii: S0190-9622(19)30627-9. doi: 10.1016/j.jaad.2019.04.035. [Epub ahead of print] Review.

PMID:
31009666
10.

Improving Estimates of Annual Survival Rates for Medial Unicompartmental Knee Arthroplasty, a Meta-Analysis.

Heaps BM, Blevins JL, Chiu YF, Konopka JF, Patel SP, McLawhorn AS.

J Arthroplasty. 2019 Jul;34(7):1538-1545. doi: 10.1016/j.arth.2019.02.061. Epub 2019 Mar 6. Review.

PMID:
30954408
11.

Oral guaifenesin for treatment of filamentary keratitis: A pilot study.

Coco G, Amparo F, Patel SP, Foulsham W, Carreno-Galeano JT, Stockslager SG, Ciolino JB, Yin J, Dana R.

Ocul Surf. 2019 Apr 1. pii: S1542-0124(19)30031-X. doi: 10.1016/j.jtos.2019.03.008. [Epub ahead of print]

PMID:
30946892
12.

Management of Immunotherapy-Related Toxicities, Version 1.2019.

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013.

PMID:
30865922
13.

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF.

J Immunother Cancer. 2019 Feb 18;7(1):49. doi: 10.1186/s40425-019-0522-3.

14.

Effects of amantadine on corneal endothelium.

Dudley CE, Morell AJ, Duffey ME, Patel SP.

Exp Eye Res. 2019 Apr;181:208-212. doi: 10.1016/j.exer.2019.02.010. Epub 2019 Feb 13.

PMID:
30771294
15.

Comparing iStent versus CyPass with or without phacoemulsification in patients with glaucoma: a meta-analysis.

Mahdavi Fard A, Patel SP, Pourafkari L, Nader ND.

Ther Adv Chronic Dis. 2019 Jan 31;10:2040622318820850. doi: 10.1177/2040622318820850. eCollection 2019.

16.

Adjuvant Ipilimumab in High-Risk Uveal Melanoma.

Fountain E, Bassett RL, Cain S, Posada L, Gombos DS, Hwu P, Bedikian A, Patel SP.

Cancers (Basel). 2019 Jan 29;11(2). pii: E152. doi: 10.3390/cancers11020152.

17.

Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.

Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, Sharon E, Denkert C, Ross JS, Adams S.

Breast. 2019 Apr;44:29-32. doi: 10.1016/j.breast.2018.12.010. Epub 2018 Dec 20.

PMID:
30609392
18.

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis.

Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z.

JAMA Oncol. 2019 Jan 3. doi: 10.1001/jamaoncol.2018.5904. [Epub ahead of print]

PMID:
30605213
19.

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.

Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F.

Cancer. 2019 Feb 1;125(3):463-472. doi: 10.1002/cncr.31812. Epub 2018 Nov 1.

PMID:
30383888
20.

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1942. doi: 10.1038/s41591-018-0252-y.

PMID:
30361511
21.

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0251-z.

PMID:
30361510
22.

Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study.

Kim K, Chung TH, Etzel CJ, Kim J, Ryu H, Kim DW, Hwu P, Hwu WJ, Patel SP, Liu M, Kim KB.

Cancer Epidemiol. 2018 Dec;57:80-84. doi: 10.1016/j.canep.2018.10.003. Epub 2018 Oct 19.

PMID:
30347335
23.

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Nov;24(11):1649-1654. doi: 10.1038/s41591-018-0197-1. Epub 2018 Oct 8. Erratum in: Nat Med. 2018 Oct 25;:. Nat Med. 2018 Oct 25;:.

24.

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.

Tran B, Carvajal RD, Marabelle A, Patel SP, LoRusso PM, Rasmussen E, Juan G, Upreti VV, Beers C, Ngarmchamnanrith G, Schöffski P.

J Immunother Cancer. 2018 Sep 25;6(1):93. doi: 10.1186/s40425-018-0407-x.

25.

Effects of taurine acute intake on cortical excitability and post-exercise facilitation: A TMS study.

Infortuna C, Milisits TF, Shaju S, Desai JK, Patel SP, Sheikh AM, Chusid E, Han Z, Battaglia F.

Behav Brain Res. 2019 Feb 1;359:719-722. doi: 10.1016/j.bbr.2018.09.014. Epub 2018 Sep 21.

PMID:
30248365
26.

Emergency Laparotomy in the Critically Ill: Futility at the Bedside.

Martin ND, Patel SP, Chreiman K, Pascual JL, Braslow B, Reilly PM, Kaplan LJ.

Crit Care Res Pract. 2018 Aug 26;2018:6398917. doi: 10.1155/2018/6398917. eCollection 2018.

27.

Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy.

Li Y, Patel SP, Roszik J, Qin Y.

Front Immunol. 2018 Jul 16;9:1591. doi: 10.3389/fimmu.2018.01591. eCollection 2018. Review.

28.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.

Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M.

J Natl Compr Canc Netw. 2018 Jul;16(7):807-821. doi: 10.6004/jnccn.2018.0062.

PMID:
30006423
29.

Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall.

Curry JL, Tetzlaff MT, Wang SA, Landon G, Alouch N, Patel SP, Nagarajan P, Gupta S, Aung PP, Devine CE, Khoury JD, Loghavi S, Prieto VG, DiNardo CD, Gershenwald JE.

Am J Dermatopathol. 2018 Nov;40(11):831-835. doi: 10.1097/DAD.0000000000001150.

PMID:
29863571
30.

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C.

Clin Cancer Res. 2018 Sep 15;24(18):4416-4428. doi: 10.1158/1078-0432.CCR-17-3649. Epub 2018 May 30.

PMID:
29848573
31.

Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment.

Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP.

Oncologist. 2018 Oct;23(10):1236-1241. doi: 10.1634/theoncologist.2017-0375. Epub 2018 May 16.

PMID:
29769383
32.

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.

Tavera RJ, Forget MA, Kim YU, Sakellariou-Thompson D, Creasy CA, Bhatta A, Fulbright OJ, Ramachandran R, Thorsen ST, Flores E, Wahl A, Gonzalez AM, Toth C, Wardell S, Mansaray R, Radvanyi LG, Gombos DS, Patel SP, Hwu P, Amaria RN, Bernatchez C, Haymaker C.

J Immunother. 2018 Nov/Dec;41(9):399-405. doi: 10.1097/CJI.0000000000000230.

PMID:
29757889
33.

Leptomeningeal disease in uveal melanoma: a case series.

Glitza IC, Reddy ST, Patel SP.

J Neurooncol. 2018 Sep;139(2):503-505. doi: 10.1007/s11060-018-2878-5. Epub 2018 Apr 27. No abstract available.

PMID:
29704079
34.

Top Ten Tips for Palliative Care Clinicians Caring for Cancer Patients Receiving Immunotherapies.

Wiesenthal AC, Patel SP, LeBlanc TW, Roeland EJ, Kamal AH.

J Palliat Med. 2018 May;21(5):694-699. doi: 10.1089/jpm.2018.0107. Epub 2018 Apr 16.

PMID:
29658821
35.

Effects of Mitochondrial Transplantation on Bioenergetics, Cellular Incorporation, and Functional Recovery after Spinal Cord Injury.

Gollihue JL, Patel SP, Eldahan KC, Cox DH, Donahue RR, Taylor BK, Sullivan PG, Rabchevsky AG.

J Neurotrauma. 2018 Aug 1;35(15):1800-1818. doi: 10.1089/neu.2017.5605. Epub 2018 Apr 30.

PMID:
29648982
36.

Obstacles to improving outcomes in the treatment of uveal melanoma.

Tsai KK, Bollin KB, Patel SP.

Cancer. 2018 Jul 1;124(13):2693-2703. doi: 10.1002/cncr.31284. Epub 2018 Mar 26. Review.

PMID:
29579316
37.

Mitochondrial transplantation strategies as potential therapeutics for central nervous system trauma.

Gollihue JL, Patel SP, Rabchevsky AG.

Neural Regen Res. 2018 Feb;13(2):194-197. doi: 10.4103/1673-5374.226382. Review.

38.

Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver.

Vera-Aguilera J, Bedikian AY, Bassett RL, Hwu WJ, Kim KB, Qin Y, Cain S, Washington EW, Davies MA, Patel SM, Homsi J, Papadopoulos NE, Hwu P, Patel SP.

Am J Clin Oncol. 2018 Mar 5. doi: 10.1097/COC.0000000000000436. [Epub ahead of print]

PMID:
29509591
39.

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.

Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL Jr, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA.

ESMO Open. 2018 Jan 24;3(1):e000283. doi: 10.1136/esmoopen-2017-000283. eCollection 2018.

40.

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA.

Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.

PMID:
29361468
41.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

42.

Targeting mitoNEET with pioglitazone for therapeutic neuroprotection after spinal cord injury.

Rabchevsky AG, Patel SP, Sullivan PG.

Neural Regen Res. 2017 Nov;12(11):1807-1808. doi: 10.4103/1673-5374.219040. No abstract available.

43.

Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.

Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R.

Cancer. 2018 Mar 15;124(6):1288-1296. doi: 10.1002/cncr.31175. Epub 2017 Dec 6.

44.

Rapamycin Exacerbates Cardiovascular Dysfunction after Complete High-Thoracic Spinal Cord Injury.

Eldahan KC, Cox DH, Gollihue JL, Patel SP, Rabchevsky AG.

J Neurotrauma. 2018 Mar 15;35(6):842-853. doi: 10.1089/neu.2017.5184. Epub 2018 Jan 29.

45.

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.

Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, Giles FJ.

Mol Cancer Ther. 2017 Dec;16(12):2645-2655. doi: 10.1158/1535-7163.MCT-17-0597. Review.

46.

Nanoparticles in thermosensitive gel based composite nanosystem for ocular diseases.

Agrahari V, Patel SP, Dhall N, Aulgur Z, Thukral S, Yang X, Conley R, Mitra AK.

Drug Deliv Transl Res. 2018 Apr;8(2):422-435. doi: 10.1007/s13346-017-0435-y.

47.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.

Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.

48.

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.

Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R.

Clin Cancer Res. 2017 Oct 1;23(19):5729-5736. doi: 10.1158/1078-0432.CCR-17-1439.

49.

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R.

Mol Cancer Ther. 2017 Nov;16(11):2598-2608. doi: 10.1158/1535-7163.MCT-17-0386. Epub 2017 Aug 23.

50.

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA.

NPJ Genom Med. 2017;2. pii: 10. doi: 10.1038/s41525-017-0013-8. Epub 2017 Apr 7.

Supplemental Content

Loading ...
Support Center